A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies

Clinical trial NCT07070323 · RECRUITING

Trial details

NCT number: NCT07070323
Sponsor: Beijing GoBroad Hospital
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

T-Cell Acute Lymphocytic Leukemia Acute Lymphoblastic Leukemia, in Relapse Refractory Acute Lymphoblastic Leukemia T-cell Malignancies

Start date: 2025-07-09
Primary completion: 2026-12-31
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.